Free Trial
OTCMKTS:BVNRY

Bavarian Nordic 8/22/2025 Earnings Report

Bavarian Nordic logo
$12.32 -0.01 (-0.08%)
As of 08/29/2025 03:38 PM Eastern

Bavarian Nordic EPS Results

Actual EPS
$0.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bavarian Nordic Revenue Results

Actual Revenue
$251.14 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bavarian Nordic Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bavarian Nordic's next earnings date is estimated for Friday, November 14, 2025, based on past reporting schedules.

Conference Call Resources

Bavarian Nordic Earnings Headlines

When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.tc pixel
Q2 2025 Bavarian Nordic A/S Earnings Call Transcript
See More Bavarian Nordic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic and other key companies, straight to your email.

About Bavarian Nordic

Bavarian Nordic (OTCMKTS:BVNRY) A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

View Bavarian Nordic Profile

More Earnings Resources from MarketBeat